7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Rajzbaum G et al. | French women, fractures and aortic calcifications. | 2005 | J. Intern. Med. | pmid:15606383 |
| Xing L et al. | Osteoclast precursors, RANKL/RANK, and immunology. | 2005 | Immunol. Rev. | pmid:16313338 |
| Tanaka S et al. | Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. | 2005 | Immunol. Rev. | pmid:16313339 |
| Horowitz MC et al. | B cells and osteoblast and osteoclast development. | 2005 | Immunol. Rev. | pmid:16313346 |
| Clowes JA et al. | The role of the immune system in the pathophysiology of osteoporosis. | 2005 | Immunol. Rev. | pmid:16313351 |
| Walsh NC et al. | Rheumatic diseases: the effects of inflammation on bone. | 2005 | Immunol. Rev. | pmid:16313352 |
| Liu Y et al. | [Effect of Herba Epimedii Flavone on expression of OPG and RANKL in rat osteoblasts]. | 2005 | Zhong Yao Cai | pmid:16568663 |
| Boyce BF et al. | Osteoprotegerin, the bone protector, is a surprising target for beta-catenin signaling. | 2005 | Cell Metab. | pmid:16330319 |
| Kieslinger M et al. | EBF2 regulates osteoblast-dependent differentiation of osteoclasts. | 2005 | Dev. Cell | pmid:16326388 |
| Yamazaki H and Sasaki T | Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice. | 2005 | J Electron Microsc (Tokyo) | pmid:16339792 |
| Wang YD et al. | [Predominant effect of bushen ningxin decoction on postmenopausal osteoporosis in mice]. | 2005 | Zhongguo Zhong Xi Yi Jie He Za Zhi | pmid:16355616 |
| Viereck V et al. | Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. | 2005 | J. Bone Miner. Res. | pmid:16234977 |
| Gajewska J et al. | [The impairement of bone formation and resorption in 25-year-old man with neglected celiac disease]. | 2005 | Wiad. Lek. | pmid:16238129 |
| Ruocco MG and Karin M | IKK{beta} as a target for treatment of inflammation induced bone loss. | 2005 | Ann. Rheum. Dis. | pmid:16239395 |
| Xiao HL et al. | [Expression and activity determination of TNFR domain of osteoprotegerin in E.coli and corresponding antibody preparation]. | 2005 | Yi Chuan | pmid:16257908 |
| Liu W et al. | Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. | 2005 | J. Biol. Chem. | pmid:16260781 |
| Hormdee D et al. | Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. | 2005 | Clin. Exp. Immunol. | pmid:16297161 |
| Dovio A et al. | Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? | 2005 | J. Endocrinol. Invest. | pmid:16550717 |
| Geusens P and Reid D | Newer drug treatments: their effects on fracture prevention. | 2005 | Best Pract Res Clin Rheumatol | pmid:16301192 |
| Hamdy NA | Osteoprotegerin as a potential therapy for osteoporosis. | 2005 | Curr Osteoporos Rep | pmid:16303111 |
| Wiercinska-Drapalo A et al. | Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. | 2005 | Prostaglandins Other Lipid Mediat. | pmid:16303613 |
| Tarquini R et al. | Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health. | 2005 | Biomed. Pharmacother. | pmid:16275499 |
| Cozzani M et al. | Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption. | 2005 | Prog Orthod | pmid:16276433 |
| Burton DW et al. | Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. | 2005 | Prostate | pmid:15389781 |
| Zahanich I et al. | Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells. | 2005 | J. Bone Miner. Res. | pmid:16059635 |
| Cao JJ et al. | Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. | 2005 | J. Bone Miner. Res. | pmid:16059637 |
| Terpos E et al. | The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. | 2005 | Leukemia | pmid:16079895 |
| Stenman UH et al. | Prognostic value of serum markers for prostate cancer. | 2005 | Scand J Urol Nephrol Suppl | pmid:16019759 |
| Guang-da X et al. | Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. | 2005 | J. Clin. Endocrinol. Metab. | pmid:16046585 |
| Kazama JJ et al. | Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. | 2005 | Clin. Nephrol. | pmid:16047647 |
| Ziegler S et al. | Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. | 2005 | Atherosclerosis | pmid:16115489 |
| Gonnelli S et al. | Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. | 2005 | J. Endocrinol. Invest. | pmid:16117195 |
| Subramaniam M et al. | TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. | 2005 | Mol. Cell. Biol. | pmid:15657444 |
| Olesen P et al. | Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. | 2005 | Diabetologia | pmid:15700136 |
| Pantouli E et al. | Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. | 2005 | Biochem. Biophys. Res. Commun. | pmid:15721297 |
| Korcok J et al. | P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. | 2005 | J. Biol. Chem. | pmid:15722352 |
| Kiviranta R et al. | Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. | 2005 | Bone | pmid:15664014 |
| Avbersek-Luznik I et al. | Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? | 2005 | Nephrol. Dial. Transplant. | pmid:15665031 |
| Bhatia P et al. | Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. | 2005 | Clin. Cancer Res. | pmid:15671541 |
| Schneider HG and Sentry J | Multiple myeloma. | 2005 | N. Engl. J. Med. | pmid:15736296 |
| Bock O et al. | Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. | 2005 | J. Pathol. | pmid:15726648 |
| Skládal P et al. | Investigation of osteoprotegerin interactions with ligands and antibodies using piezoelectric biosensors. | 2005 | Biosens Bioelectron | pmid:15741072 |
| Mosheimer BA et al. | Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. | 2005 | J. Clin. Endocrinol. Metab. | pmid:15728209 |
| Kanno T et al. | Platelet-rich plasma enhances human osteoblast-like cell proliferation and differentiation. | 2005 | J. Oral Maxillofac. Surg. | pmid:15742288 |
| Han KO et al. | The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. | 2005 | Clin. Endocrinol. (Oxf) | pmid:15730418 |
| Nagasaki T et al. | Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. | 2005 | Eur. J. Endocrinol. | pmid:15757850 |
| Simmons CA et al. | Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. | 2005 | Circ. Res. | pmid:15761200 |
| Gallant MA et al. | Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. | 2005 | J. Bone Miner. Res. | pmid:15765187 |
| Moe SM et al. | Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). | 2005 | Kidney Int. | pmid:15882271 |
| Ueland T et al. | Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. | 2005 | Circulation | pmid:15883214 |
| Sabokbar A et al. | Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening. | 2005 | J. Orthop. Res. | pmid:15885469 |
| Morony S et al. | The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. | 2005 | Endocrinology | pmid:15845617 |
| Rhee EJ et al. | The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. | 2005 | Am. J. Obstet. Gynecol. | pmid:15846185 |
| Bord S et al. | Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. | 2005 | Bone | pmid:15794927 |
| Rasmussen LM and Ledet T | Osteoprotegerin and diabetic macroangiopathy. | 2005 | Horm. Metab. Res. | pmid:15918117 |
| Tanabe N et al. | IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. | 2005 | Life Sci. | pmid:15921993 |
| Zhou YQ et al. | [OPG and OPGL expression in condyle cartilage of temporomandibular joint following anterior disc displacement]. | 2005 | Shanghai Kou Qiang Yi Xue | pmid:16155701 |
| Crisafulli A et al. | Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. | 2005 | Clin. Sci. | pmid:15926884 |
| Holen I et al. | Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? | 2005 | Breast Cancer Res. Treat. | pmid:16155791 |
| Mahamed DA et al. | G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. | 2005 | Diabetes | pmid:15855336 |
| Hong JS et al. | Maternal plasma osteoprotegerin concentration in normal pregnancy. | 2005 | Am. J. Obstet. Gynecol. | pmid:16157103 |
| Leder BZ and Finkelstein JS | Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. | 2005 | Osteoporos Int | pmid:15856361 |
| Mazziotti G et al. | Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. | 2005 | J. Bone Miner. Res. | pmid:15746993 |
| Galli C et al. | Comparison of human mandibular osteoblasts grown on two commercially available titanium implant surfaces. | 2005 | J. Periodontol. | pmid:15857069 |
| Stolina M et al. | RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. | 2005 | J. Bone Miner. Res. | pmid:16160733 |
| Corey E et al. | Osteoprotegerin in prostate cancer bone metastasis. | 2005 | Cancer Res. | pmid:15753366 |
| Suzuki K et al. | Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. | 2005 | Diabetes Res. Clin. Pract. | pmid:15860239 |
| Yasuda H | [OPG, anti-rANKL antibody]. | 2005 | Nippon Rinsho | pmid:16164225 |
| Moschen AR et al. | The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. | 2005 | Gut | pmid:15753532 |
| Choi BK et al. | Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii. | 2005 | J. Periodontol. | pmid:15898943 |
| Moschen AR et al. | The RANKL/OPG system and bone mineral density in patients with chronic liver disease. | 2005 | J. Hepatol. | pmid:16143421 |
| Mandelin J et al. | Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation. | 2005 | J. Biomed. Mater. Res. Part B Appl. Biomater. | pmid:15768436 |
| Carda C et al. | Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint. | 2005 | Tissue Cell | pmid:15899507 |
| Crisafulli A et al. | Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. | 2005 | Menopause | pmid:15772566 |
| Mizuno N et al. | Characterization of epithelial cells derived from periodontal ligament by gene expression patterns of bone-related and enamel proteins. | 2005 | Cell Biol. Int. | pmid:15774307 |
| Indridason OS et al. | Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. | 2005 | Osteoporos Int | pmid:15776220 |
| Ling LJ et al. | Areca nut extracts modulated expression of alkaline phosphatase and receptor activator of nuclear factor kappaB ligand in osteoblasts. | 2005 | J. Clin. Periodontol. | pmid:15811051 |
| Maïmoun L et al. | Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. | 2005 | Calcif. Tissue Int. | pmid:15812577 |
| Ulrich-Vinther M and Andreassen TT | Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. | 2005 | Calcif. Tissue Int. | pmid:15812581 |
| Meng XM et al. | [Expression of receptor activator of NF-kappa B ligand and osteoprotegerin protein in the giant cell lesions of jaw]. | 2005 | Zhonghua Kou Qiang Yi Xue Za Zhi | pmid:16191370 |
| Khosla S | Magic bullets to kill nasty osteoclasts. | 2005 | Endocrinology | pmid:16009971 |
| Tabuchi M et al. | Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. | 2005 | Calcif. Tissue Int. | pmid:16193235 |
| Feng X | RANKing intracellular signaling in osteoclasts. | 2005 | IUBMB Life | pmid:16012047 |
| Kusumi A et al. | Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain. | 2005 | J. Bone Miner. Metab. | pmid:16133687 |
| Moran CS et al. | Association of osteoprotegerin with human abdominal aortic aneurysm progression. | 2005 | Circulation | pmid:15939823 |
| Deftos LJ | Treatment of Paget's disease--taming the wild osteoclast. | 2005 | N. Engl. J. Med. | pmid:16135831 |
| Li F et al. | Annexin II stimulates RANKL expression through MAPK. | 2005 | J. Bone Miner. Res. | pmid:15940368 |
| Cundy T et al. | Recombinant osteoprotegerin for juvenile Paget's disease. | 2005 | N. Engl. J. Med. | pmid:16135836 |
| Sen O et al. | The relation between serum levels of osteoprotegerin and postoperative epidural fibrosis in patients who underwent surgery for lumbar disc herniation. | 2005 | Neurol. Res. | pmid:15949247 |
| Rhee EJ et al. | Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. | 2005 | Clin. Sci. | pmid:15569000 |
| Bock O et al. | Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. | 2005 | Br. J. Haematol. | pmid:15982347 |
| Heinrich J et al. | CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption. | 2005 | Arch. Oral Biol. | pmid:16137499 |
| Fiore CE et al. | Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. | 2005 | Osteoporos Int | pmid:15983730 |
| Avignon A et al. | Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. | 2005 | Diabetes Care | pmid:16123486 |
| Atkins GJ et al. | Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. | 2005 | J. Cell. Physiol. | pmid:15573398 |
| Amizuka N et al. | Histological evaluation for "bone quality" on two mouse models with different bone remodeling. | 2005 | J. Bone Miner. Metab. | pmid:15984413 |
| Ziegler S et al. | Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand. | 2005 | Metab. Clin. Exp. | pmid:15988704 |
| Sakai A et al. | Osteoclast development in immobilized bone is suppressed by parathyroidectomy in mice. | 2005 | J. Bone Miner. Metab. | pmid:15616888 |
| Sasaki N et al. | Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). | 2005 | J. Bone Miner. Metab. | pmid:15616893 |
| Masui T et al. | Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. | 2005 | Biomaterials | pmid:15576143 |